Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

NCT05356195 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia
Thalassemia
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies

Interventions

BIOLOGICAL: CTX001

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]